Novocure Shares Rise 17% After FDA Accepts Pre-Market Application
By Ben Glickman
Shares of Novocure rose Thursday after U.S. regulators accepted a pre-market application for the company's lung-cancer therapy.
The stock was up 17% to $14.52 in recent trading. Shares are down 63% in the last six months.
The Root, Switzerland-based cancer-treatment developer said Thursday that the U.S. Food and Drug Administration had accepted its Premarket Approval application for the use of Tumor Treating Fields therapy to treat non-small cell lung cancer.
Novocure is expecting a decision from the FDA in the second half of 2024.
The company's trial data, which was submitted to the FDA for review, tested the safety and effectiveness of TTFields therapy in combination with standard systemic therapies in treating NSCLC following progression after receiving platinum-based therapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 10:55 ET (15:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?